Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW). Click here to learn more.
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors. Click here to learn more.
ES2018 Blood Collection from Exact Sciences / ICON
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors. Click here to learn more.
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions. Click here to learn more.
Molecular Analysis for Therapy Choice (MATCH). Click here to learn more.
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion. Click here to learn more.
An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PDL-1, and CTLA-4) used as Monotherapy or in Combination in Patients with Cancer. Ask your doctor.
A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors. Click here to learn more.
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). Click here to learn more.